Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialStefan Bielack, Mark L. Bernstein, Susan Picton et al.|Journal of Clinical Oncology|2015Cited by 419
Appropriate Use Criteria for <sup>18</sup>F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant DiseaseHossein Jadvar, Landis K. Griffeth, Andrei Iagaru et al.|Journal of Nuclear Medicine|2017Cited by 99
2024 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical ActivitiesS. Ted Treves, Katherine Zukotynski, Frederick D. Grant et al.|Journal of Nuclear Medicine Technology|2025Cited by 97
Management of Differentiated Thyroid Cancer: The Standard of CareAnca M. Avram, Luca Giovanella, Helen Nadel et al.|Journal of Nuclear Medicine|2021Cited by 59